20
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T72013 | Epigenetic Multiple Ligand | ||
Epigenetic Multiple Ligand is a cell-permeable inhibitor of substrate processing by several chromatin-associated enzymes, including SIRT1/2, H3/SET7, H3/p300/CBP, H4/RmtA, PABP1/CARM1, and H4/PRMT1. It acts by inducing e... | |||
T82458 | Epigenetic factor-IN-1 | Sirtuin | |
Epigenetic factor-IN-1 (40569Z) is an epigenetic factor inhibitor that exhibits potent binding affinity for SIRT7. It is utilized in the study of liver cancer [1]. | |||
T15424 | GSK1379725A | Epigenetic Reader Domain | |
GSK1379725A is a selective BPTF ligand (Kd: 2.8 uM). It also shows no binding activity for Brd4. | |||
T11925 | M‑89 | Epigenetic Reader Domain , Histone Methyltransferase | |
M-89, a highly potent and specific inhibitor of the menin-mixed lineage leukemia (Menin-MLL) protein-protein interaction, exhibits a Kd of 1.4 nM for menin binding. This compound holds potential for treating MLL leukemia... | |||
T2072 | BET bromodomain inhibitor | Epigenetic Reader Domain | |
BET bromodomain inhibitor is a potent BET inhibitor. | |||
T5440 | Dbet57 | Epigenetic Reader Domain | |
dBET57 is heterobifunctional degrader of BRD4 based on the PROTAC technology, exhibits significant degradation of BRD4BD1 with a DC50/5h of 500 nM ,and inactive on BRD4BD2 | |||
T4495 | DBET1 | Epigenetic Reader Domain | |
dBET1 is a hybrid molecule that combines (+)-JQ1 and thalidomide. It induces cereblon-dependent BET protein degradation in vitro (EC50: 430 nM) and induces apoptosis. | |||
T6668 | SGC-CBP30 | Epigenetic Reader Domain , Histone Acetyltransferase | |
SGC-CBP30 is an effective CREBBP/EP300 inhibitor (IC50: 21/38 nM). | |||
T5130 | DBET6 | Apoptosis , Epigenetic Reader Domain | |
dBET6 is a selective and cell-permeable degrader of BET based on PROTAC (IC50: 14 nM). It has antitumor activity. | |||
T6783 | BI-7273 | Epigenetic Reader Domain | |
BI-7273 is an effective, specific, BRD9 BD Inhibitor, which can infiltrate cell. | |||
TQ0083 | NI-57 | Epigenetic Reader Domain | |
NI-57 is an inhibitor of proteins of bromodomain and plant homeodomain finger-containing (BRPF) family, with IC50s of 3.1, 46 and 140 nM for BRPF1, BRPF2 (BRD1) and BRPF3, respectively. | |||
TQ0253 | PLX51107 | Epigenetic Reader Domain | |
PLX51107 is a potent and selective BET inhibitor (Kds: 1.6, 2.1, 1.7, and 5 nM for BRD2-BD1, BRD3-BD1, BRD4-BD1, and BRDT-BD1). | |||
T12112 | MS402 | Epigenetic Reader Domain | |
MS402 is a novel BD1-selective BET BrD inhibitor. | |||
TQ0069 | MI-503 | Epigenetic Reader Domain , Histone Methyltransferase | |
MI-503 is a highly effective and orally bioavailable inhibitor of the menin-mLL interaction. | |||
T16321 | NI-42 | Epigenetic Reader Domain | |
NI-42 is a structurally orthogonal chemical probe for the BRPFs and is biased. It effective inhibitor of the BRD of the BRPFs (IC50s of BRPF1/2/3=7.9/48/260 nM; Kds of BRPF1/2/3=40/210/940 nM). It also has excellent sele... | |||
T9749 | FHD-286 | Epigenetic Reader Domain | |
FHD-286 is an inhibitor of BRM/BRG1 ATPase and can be used for studies on the treatment of BAF-related disorders such as acute myeloid leukemia. | |||
T2127 | OF-1 | Epigenetic Reader Domain | |
OF-1 is a potent inhibitor of BRPF1B and BRPF2 bromodomain. | |||
T3311 | GSK6853 | Epigenetic Reader Domain | |
GSK6853 is a potent, soluble, cell-active, and highly selective inhibitor of the BRPF1 bromodomain. | |||
TQ0058 | MI-463 | Epigenetic Reader Domain , Histone Methyltransferase | |
MI-463 is a potent and orally bioavailable inhibitor of the menin-mLL interaction (IC50: 15.3 nM). | |||
T16072 | MI-538 | Epigenetic Reader Domain , Histone Methyltransferase | |
MI-538 is an interaction between menin and MLL fusion proteins inhibitor(IC50 of 21 nM). |